TXMD
TherapeuticsMD, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · NMS
$1.99
Data: 2026-05-23
✗ ETHICAL FAIL
WEAK MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$25M
Total market value of the company
Rev Growth
+84.2%
Year-over-year revenue change
Profit Margin
5.3%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About TherapeuticsMD, Inc.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
19.7% PASS
Debt must be below 33% of total assets
Cash Ratio
34.3% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
Overall assessment combining ethics, valuation, and quality
Ethical Score
N/A
Valuation Score
95.0
Quality Score
54.0
Combined
57.8
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-2.1%
Historical annualised return based on price data
Days in State
34
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-23 | THOMPSON TOMMY G | Director | 8,400 | $14,031 | |
| 2025-04-14 | THOMPSON TOMMY G | Director | 325 | $326 | |
| 2025-04-14 | WALKER MARLAN D | Chief Executive Officer | 490 | $489 | |
| 2025-04-10 | WALKER MARLAN D | Chief Executive Officer | 2,303 | $1,994 | |
| 2025-02-18 | NAUGHTON GAIL K | Director | 8,500 | — | |
| 2025-02-18 | THOMPSON TOMMY G | Director | 8,500 | — | |
| 2025-02-18 | COLLINS COOPER C | Director | 8,500 | — | |
| 2025-02-18 | WALKER MARLAN D | Chief Executive Officer | 8,281 | — | |
| 2024-08-22 | COLLINS COOPER C | Director | 4,094 | $7,099 | |
| 2024-08-21 | COLLINS COOPER C | Director | 1,200 | $2,039 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-23